Results 181 to 190 of about 20,820 (198)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis

Gut, 2020
Sung Won Lee, Jung Hyun Kwon, Hae Lim Lee   +2 more
exaly  

Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

Science Translational Medicine, 2012
Peter L Anderson, David V Glidden, Albert Y Liu   +2 more
exaly  

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Lancet, The, 2015
Paul E Sax, Michael T Yin, Fa Post
exaly  

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet Gastroenterology and Hepatology, 2016
Maria Buti, Henry Lik Yuen Chan, Wan-Long Chuang   +2 more
exaly  

Tenofovir-disoproxil-fumarate

Reactions Weekly, 2022
openaire   +1 more source

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Lancet, The, 2017
Paul E Sax, Anton L Pozniak, Andrea Antinori   +2 more
exaly  

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

Lancet HIV,the, 2020
Simiso Sokhela, Bryony Simmons, Michelle A Moorhouse   +2 more
exaly  

Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission

Science Translational Medicine, 2011
Nicholas J Shaheen, Angela D M Kashuba
exaly  

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

Hepatology, 2017
George Papatheodoridis, Ramazan Idilman, George N Dalekos   +2 more
exaly  

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Lancet Infectious Diseases, The, 2016
Jose R Arribas, Matthias Cavassini, Chloe Orkin   +2 more
exaly